Where Will Hershey Stock Be In 1 Year?
Chocolate stocks used to be the epitome of sleepy stability,…
Sell
43
OSTX Quote, Financials, Valuation and Earnings
Last price:
$1.90
Seasonality move
:
--
Day range:
$1.87 - $1.95
52-week range:
$1.12 - $7.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
162.9K
Avg. volume:
322.4K
1-year change:
--
Market cap:
$54.2M
Revenue:
--
EPS (TTM):
-$0.67
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
OSTX
OS Therapies
|
-- | -$0.12 | -- | -19.03% | $13.50 |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$0.35 | -100% | -7.24% | $5.00 |
|
CTOR
Citius Oncology
|
-- | -- | -- | -- | $3.00 |
|
CVM
CEL-SCI
|
-- | -- | -- | -- | $8.00 |
|
MBOT
Microbot Medical
|
-- | -$0.08 | -- | -29.41% | $9.00 |
|
NEOG
Neogen
|
$222.5M | $0.09 | -6.02% | 800% | $7.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
OSTX
OS Therapies
|
$1.93 | $13.50 | $54.2M | -- | $0.00 | 0% | -- |
|
ATNM
Actinium Pharmaceuticals
|
$1.35 | $5.00 | $42.1M | -- | $0.00 | 0% | -- |
|
CTOR
Citius Oncology
|
$5.19 | $3.00 | $371.4M | -- | $0.00 | 0% | -- |
|
CVM
CEL-SCI
|
$2.37 | $8.00 | $7.2M | -- | $0.00 | 0% | -- |
|
MBOT
Microbot Medical
|
$2.49 | $9.00 | $90.6M | -- | $0.00 | 0% | -- |
|
NEOG
Neogen
|
$5.08 | $7.50 | $1.1B | 2,124.15x | $0.00 | 0% | 1.22x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
OSTX
OS Therapies
|
-- | 0.000 | -- | -- |
|
ATNM
Actinium Pharmaceuticals
|
-- | -3.037 | -- | 9.03x |
|
CTOR
Citius Oncology
|
-- | 9.770 | -- | -- |
|
CVM
CEL-SCI
|
-- | -0.752 | -- | -- |
|
MBOT
Microbot Medical
|
-- | -0.516 | -- | -- |
|
NEOG
Neogen
|
25.08% | 2.034 | 40.83% | 2.04x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
OSTX
OS Therapies
|
-- | -$5M | -- | -- | -- | -$3.6M |
|
ATNM
Actinium Pharmaceuticals
|
-- | -$16.6M | -95.08% | -95.08% | -12769.14% | -$7.6M |
|
CTOR
Citius Oncology
|
-- | -$7.5M | -- | -- | -- | -- |
|
CVM
CEL-SCI
|
-- | -$6.4M | -- | -- | -- | -$4.4M |
|
MBOT
Microbot Medical
|
-- | -$3M | -- | -- | -- | -$2.9M |
|
NEOG
Neogen
|
$110.3M | $5.4M | -12.64% | -16.44% | 3.63% | -$13.5M |
OS Therapies vs. Competitors
-
Which has Higher Returns OSTX or ATNM?
Actinium Pharmaceuticals has a net margin of -- compared to OS Therapies's net margin of -11511.11%. OS Therapies's return on equity of -- beat Actinium Pharmaceuticals's return on equity of -95.08%.
Company Gross Margin Earnings Per Share Invested Capital OSTXOS Therapies-- -$0.18 -- ATNMActinium Pharmaceuticals-- -$0.51 $36.4M -
What do Analysts Say About OSTX or ATNM?
OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 599.48%. On the other hand Actinium Pharmaceuticals has an analysts' consensus of $5.00 which suggests that it could grow by 270.37%. Given that OS Therapies has higher upside potential than Actinium Pharmaceuticals, analysts believe OS Therapies is more attractive than Actinium Pharmaceuticals.
Company Buy Ratings Hold Ratings Sell Ratings OSTXOS Therapies3 0 0 ATNMActinium Pharmaceuticals2 1 0 -
Is OSTX or ATNM More Risky?
OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Actinium Pharmaceuticals has a beta of -0.325, suggesting its less volatile than the S&P 500 by 132.486%.
-
Which is a Better Dividend Stock OSTX or ATNM?
OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Actinium Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. Actinium Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OSTX or ATNM?
OS Therapies quarterly revenues are --, which are smaller than Actinium Pharmaceuticals quarterly revenues of $81K. OS Therapies's net income of -$3.9M is higher than Actinium Pharmaceuticals's net income of -$15.9M. Notably, OS Therapies's price-to-earnings ratio is -- while Actinium Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus -- for Actinium Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OSTXOS Therapies-- -- -- -$3.9M ATNMActinium Pharmaceuticals-- -- $81K -$15.9M
-
Which has Higher Returns OSTX or CTOR?
Citius Oncology has a net margin of -- compared to OS Therapies's net margin of --. OS Therapies's return on equity of -- beat Citius Oncology's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OSTXOS Therapies-- -$0.18 -- CTORCitius Oncology-- -$0.11 -- -
What do Analysts Say About OSTX or CTOR?
OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 599.48%. On the other hand Citius Oncology has an analysts' consensus of $3.00 which suggests that it could fall by -42.2%. Given that OS Therapies has higher upside potential than Citius Oncology, analysts believe OS Therapies is more attractive than Citius Oncology.
Company Buy Ratings Hold Ratings Sell Ratings OSTXOS Therapies3 0 0 CTORCitius Oncology0 1 0 -
Is OSTX or CTOR More Risky?
OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Citius Oncology has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock OSTX or CTOR?
OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Oncology offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. Citius Oncology pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OSTX or CTOR?
OS Therapies quarterly revenues are --, which are smaller than Citius Oncology quarterly revenues of --. OS Therapies's net income of -$3.9M is higher than Citius Oncology's net income of -$7.7M. Notably, OS Therapies's price-to-earnings ratio is -- while Citius Oncology's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus -- for Citius Oncology. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OSTXOS Therapies-- -- -- -$3.9M CTORCitius Oncology-- -- -- -$7.7M
-
Which has Higher Returns OSTX or CVM?
CEL-SCI has a net margin of -- compared to OS Therapies's net margin of --. OS Therapies's return on equity of -- beat CEL-SCI's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OSTXOS Therapies-- -$0.18 -- CVMCEL-SCI-- -$2.40 -- -
What do Analysts Say About OSTX or CVM?
OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 599.48%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 10027.6%. Given that CEL-SCI has higher upside potential than OS Therapies, analysts believe CEL-SCI is more attractive than OS Therapies.
Company Buy Ratings Hold Ratings Sell Ratings OSTXOS Therapies3 0 0 CVMCEL-SCI1 0 0 -
Is OSTX or CVM More Risky?
OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.097%.
-
Which is a Better Dividend Stock OSTX or CVM?
OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OSTX or CVM?
OS Therapies quarterly revenues are --, which are smaller than CEL-SCI quarterly revenues of --. OS Therapies's net income of -$3.9M is higher than CEL-SCI's net income of -$6.6M. Notably, OS Therapies's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OSTXOS Therapies-- -- -- -$3.9M CVMCEL-SCI-- -- -- -$6.6M
-
Which has Higher Returns OSTX or MBOT?
Microbot Medical has a net margin of -- compared to OS Therapies's net margin of --. OS Therapies's return on equity of -- beat Microbot Medical's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital OSTXOS Therapies-- -$0.18 -- MBOTMicrobot Medical-- -$0.08 -- -
What do Analysts Say About OSTX or MBOT?
OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 599.48%. On the other hand Microbot Medical has an analysts' consensus of $9.00 which suggests that it could grow by 261.45%. Given that OS Therapies has higher upside potential than Microbot Medical, analysts believe OS Therapies is more attractive than Microbot Medical.
Company Buy Ratings Hold Ratings Sell Ratings OSTXOS Therapies3 0 0 MBOTMicrobot Medical0 0 0 -
Is OSTX or MBOT More Risky?
OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Microbot Medical has a beta of 1.127, suggesting its more volatile than the S&P 500 by 12.737%.
-
Which is a Better Dividend Stock OSTX or MBOT?
OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Microbot Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. Microbot Medical pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OSTX or MBOT?
OS Therapies quarterly revenues are --, which are smaller than Microbot Medical quarterly revenues of --. OS Therapies's net income of -$3.9M is lower than Microbot Medical's net income of -$2.6M. Notably, OS Therapies's price-to-earnings ratio is -- while Microbot Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus -- for Microbot Medical. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OSTXOS Therapies-- -- -- -$3.9M MBOTMicrobot Medical-- -- -- -$2.6M
-
Which has Higher Returns OSTX or NEOG?
Neogen has a net margin of -- compared to OS Therapies's net margin of -4.96%. OS Therapies's return on equity of -- beat Neogen's return on equity of -16.44%.
Company Gross Margin Earnings Per Share Invested Capital OSTXOS Therapies-- -$0.18 -- NEOGNeogen49.9% -$0.05 $3.6B -
What do Analysts Say About OSTX or NEOG?
OS Therapies has a consensus price target of $13.50, signalling upside risk potential of 599.48%. On the other hand Neogen has an analysts' consensus of $7.50 which suggests that it could grow by 47.64%. Given that OS Therapies has higher upside potential than Neogen, analysts believe OS Therapies is more attractive than Neogen.
Company Buy Ratings Hold Ratings Sell Ratings OSTXOS Therapies3 0 0 NEOGNeogen2 1 0 -
Is OSTX or NEOG More Risky?
OS Therapies has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Neogen has a beta of 1.771, suggesting its more volatile than the S&P 500 by 77.099%.
-
Which is a Better Dividend Stock OSTX or NEOG?
OS Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Neogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. OS Therapies pays -- of its earnings as a dividend. Neogen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios OSTX or NEOG?
OS Therapies quarterly revenues are --, which are smaller than Neogen quarterly revenues of $221M. OS Therapies's net income of -$3.9M is higher than Neogen's net income of -$11M. Notably, OS Therapies's price-to-earnings ratio is -- while Neogen's PE ratio is 2,124.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for OS Therapies is -- versus 1.22x for Neogen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income OSTXOS Therapies-- -- -- -$3.9M NEOGNeogen1.22x 2,124.15x $221M -$11M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will KNOT Stock Be In 1 Year?
In the case of KNOT Offshore Partners (KNOP), most headlines…
Why Is Goldman Sachs Stock Up So Much?
Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…
Stock Ideas
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 52x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Alerts
Buy
60
AEVA alert for Jul 3
Aeva Technologies [AEVA] is up 7.78% over the past day.
Sell
44
PRGS alert for Jul 2
Progress Software [PRGS] is down 2.94% over the past day.
Sell
46
NAIL alert for Jul 2
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 3.1% over the past day.
